Central Library

Biopharmaceutical manufacturing. (Record no. 82912)

000 -LEADER
fixed length control field 05883nam a2200745 i 4500
001 - CONTROL NUMBER
control field 9780750331791
003 - CONTROL NUMBER IDENTIFIER
control field IOP
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20230516170312.0
006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS
fixed length control field m eo d
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr cn |||m|||a
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 220301s2022 enka fob 000 0 eng d
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9780750331791
Qualifying information ebook
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9780750331784
Qualifying information mobi
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
Canceled/invalid ISBN 9780750331777
Qualifying information print
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
Canceled/invalid ISBN 9780750331807
Qualifying information myPrint
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.1088/978-0-7503-3179-1
Source of number or code doi
035 ## - SYSTEM CONTROL NUMBER
System control number (CaBNVSL)mat00083165
035 ## - SYSTEM CONTROL NUMBER
System control number (OCoLC)1303069435
040 ## - CATALOGING SOURCE
Original cataloging agency CaBNVSL
Language of cataloging eng
Description conventions rda
Transcribing agency CaBNVSL
Modifying agency CaBNVSL
050 #4 - LIBRARY OF CONGRESS CALL NUMBER
Classification number RS380
Item number .N533 2021eb vol. 2
060 #4 - NATIONAL LIBRARY OF MEDICINE CALL NUMBER
Classification number QV 778
Item number N577b 2021eb vol. 2
072 #7 - SUBJECT CATEGORY CODE
Subject category code TDCW
Source bicssc
072 #7 - SUBJECT CATEGORY CODE
Subject category code TEC020000
Source bisacsh
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 615.19
Edition number 23
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Niazi, Sarfaraz,
Dates associated with a name 1949-
Relator term author.
9 (RLIN) 70827
245 10 - TITLE STATEMENT
Title Biopharmaceutical manufacturing.
Number of part/section of a work Volume 2,
Name of part/section of a work Unit processes /
Statement of responsibility, etc. Sarfaraz Niazi, Sunitha Lokesh.
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Place of production, publication, distribution, manufacture Bristol [England] (Temple Circus, Temple Way, Bristol BS1 6HG, UK) :
Name of producer, publisher, distributor, manufacturer IOP Publishing,
Date of production, publication, distribution, manufacture, or copyright notice [2022]
300 ## - PHYSICAL DESCRIPTION
Extent 1 online resource (various pagings) :
Other physical details illustrations (some color).
336 ## - CONTENT TYPE
Content type term text
Source rdacontent
337 ## - MEDIA TYPE
Media type term electronic
Source isbdmedia
338 ## - CARRIER TYPE
Carrier type term online resource
Source rdacarrier
490 1# - SERIES STATEMENT
Series statement [IOP release $release]
490 1# - SERIES STATEMENT
Series statement IOP ebooks. [2022 collection]
500 ## - GENERAL NOTE
General note "Version: 202201"--Title page verso.
504 ## - BIBLIOGRAPHY, ETC. NOTE
Bibliography, etc. note Includes bibliographical references.
505 0# - FORMATTED CONTENTS NOTE
Formatted contents note 1. Understanding bioprocessing -- 1.1. Overview -- 1.2. Key considerations for the production of biotherapeutics -- 1.3. Chromatography methods -- 1.4. Process lifecycle -- 1.5. Costing -- 1.6. Facility design -- 1.7. Testing -- 1.8. Documentation process -- 1.9. Conclusion
505 8# - FORMATTED CONTENTS NOTE
Formatted contents note 2. Recombinant manufacturing system -- 2.1. Overview -- 2.2. Recombinant DNA -- 2.3. Expression systems -- 2.4. Conclusion
505 8# - FORMATTED CONTENTS NOTE
Formatted contents note 3. Cell line development -- 3.1. Overview -- 3.2. Overview of protein expression -- 3.3. Host cell engineering -- 3.4. Conclusion -- 3.5. Appendix
505 8# - FORMATTED CONTENTS NOTE
Formatted contents note 4. Upstream equipment and systems -- 4.1. Overview -- 4.2. Medium and solution preparation systems -- 4.3. Bioreactor systems -- 4.4. Harvest and clarification systems -- 4.5. Ancillary and peripheral equipment -- 4.6. Conclusion
505 8# - FORMATTED CONTENTS NOTE
Formatted contents note 5. Upstream processing -- 5.1. Overview -- 5.2. Culture media -- 5.3. Cell culture fermentation -- 5.4. Conclusion
505 8# - FORMATTED CONTENTS NOTE
Formatted contents note 6. Downstream process -- 6.1. Overview -- 6.2. E. coli system : recovery and purification -- 6.3. Mammalian system purification -- 6.4. Product concentration -- 6.5. Analytical methods -- 6.6. Downstream processing equipment and system components -- 6.7. Conclusion
505 8# - FORMATTED CONTENTS NOTE
Formatted contents note 7. Process and product lifecycle development -- 7.1. Overview -- 7.2. Process development -- 7.3. Process scale-up -- 7.4. Technology transfer -- 7.5. Process characterization and optimization -- 7.6. Process validation -- 7.7. Process control strategy -- 7.8. Testing methods -- 7.9. Conclusion
505 8# - FORMATTED CONTENTS NOTE
Formatted contents note 8. Quality and compliance systems -- 8.1. Overview -- 8.2. Quality system -- 8.3. Validation master plan -- 8.4. Good laboratory practices -- 8.5. Quality control -- 8.6. Regulatory compliance -- 8.7. Conclusion
505 8# - FORMATTED CONTENTS NOTE
Formatted contents note 9. Single-use technology -- 9.1. Overview -- 9.2. Single-use containers and mixing systems -- 9.3. Upstream processing -- 9.4. Connectors and transfer systems -- 9.5. Sampling -- 9.6. Downstream processing -- 9.7. Safety -- 9.8. Regulatory matters -- 9.9. Advantages -- 9.10. Conclusion
505 8# - FORMATTED CONTENTS NOTE
Formatted contents note 10. Advancements and trends in biomanufacturing -- 10.1. Overview -- 10.2. Cell line development -- 10.3. Upstream process intensification -- 10.4. Downstream -- 10.5. Continuous manufacturing -- 10.6. Process analytical technology (PAT) -- 10.7. Automation -- 10.8. Conclusion.
520 3# - SUMMARY, ETC.
Summary, etc. This two-volume set provides a comprehensive guide to the essential aspects of commercial biopharmaceutical manufacturing. Covering the planning, layout and operation of successful commercial manufacturing, the aim of the books is to enable innovations, new drug development, and make affordable biological drugs available to patients worldwide. This volume covers the unit processes involved in producing a GMP (Good Manufacturing Practice) biopharmaceutical product, laid out in the order of operation, with complete details on equipment, compliance and yield improvement suggestions.
521 ## - TARGET AUDIENCE NOTE
Target audience note Industry scientists, engineers, investors, developers and other manufacturers of biopharmaceutical products.
530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE
Additional physical form available note Also available in print.
538 ## - SYSTEM DETAILS NOTE
System details note Mode of access: World Wide Web.
538 ## - SYSTEM DETAILS NOTE
System details note System requirements: Adobe Acrobat Reader, EPUB reader, or Kindle reader.
545 ## - BIOGRAPHICAL OR HISTORICAL DATA
Biographical or historical data Sarfaraz K. Niazi is an adjunct professor at the University of Illinois and University of Houston. Prof. Niazi has established numerous consulting businesses and start-up companies within the biopharmaceutical industry, including Pharmaceutical Scientist, Inc and Karyo Biologics, LLC. Sunitha Lokesh is the director of biomanufacturing operations at Pharmaceutical Scientist Inc., where she leads the identification and technology development of biopharmaceutical products.
588 0# - SOURCE OF DESCRIPTION NOTE
Source of description note Title from PDF title page (viewed on March 8, 2022).
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Pharmaceutical biotechnology.
9 (RLIN) 14618
650 12 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Technology, Pharmaceutical.
9 (RLIN) 8637
650 12 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Biotechnology.
9 (RLIN) 7533
650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Pharmaceutical technology.
Source of heading or term bicssc
9 (RLIN) 7812
650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Biomedical engineering.
Source of heading or term bisacsh
9 (RLIN) 3292
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Lokesh, Sunitha,
Relator term author.
9 (RLIN) 70828
710 2# - ADDED ENTRY--CORPORATE NAME
Corporate name or jurisdiction name as entry element Institute of Physics (Great Britain),
Relator term publisher.
9 (RLIN) 11622
776 08 - ADDITIONAL PHYSICAL FORM ENTRY
Relationship information Print version:
International Standard Book Number 9780750331777
-- 9780750331807
830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE
Uniform title IOP (Series).
Name of part/section of a work Release 22.
9 (RLIN) 70829
830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE
Uniform title IOP ebooks.
Name of part/section of a work 2022 collection.
9 (RLIN) 70830
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://iopscience.iop.org/book/978-0-7503-3179-1">https://iopscience.iop.org/book/978-0-7503-3179-1</a>
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Koha item type eBooks

No items available.